[DAILY TRADING] Pfizer Stock Price Today 21 August 2026 – $27.82 After CEO’s $1M Share Purchase

This piece reads the Vantage Pfizer CFD chart as it stands right now. It translates the price action; it does not call a trade. All prices are as of 08:58 UTC on 21 August 2026 and are indicative only.

Pfizer (NYSE: PFE) is trading at $27.82 as of 08:58 (UTC) / 16:58 (GMT+8) on 21 August 2026, essentially flat at -0.04%, with pre-market pricing at $27.73. The real story isn’t the move, it’s where the stock sits: wedged between its rising 50-period moving average and a 200-period average still hovering overhead. The setup follows a strong Q2 earnings beat, a constructive BMO Capital note, and a well-timed $1 million share purchase from CEO Albert Bourla, part of the wider Pfizer stock news today cycle.

Key Points

• Pfizer shares traded at $27.82 as of 08:58 (UTC) / 16:58 (GMT+8) on 21 August 2026, holding above the 50-period moving average at 27.11 but below the 200-period moving average at 28.07 on the TradingView setup used for this analysis.
• Second-quarter 2026 results, reported on 4 August 2026, showed revenue of $15.03 billion, and the company raised the midpoint of its full-year 2026 revenue guidance. ^[1][7]
• CEO Albert Bourla purchased 38,000 Pfizer shares at $26.34 each on 12 August 2026, an open-market transaction worth approximately $1 million, disclosed in a Form 4 filing. ^[6]

Pfizer stock traded at $27.82 as of 21 August 2026, sitting between its 50-period moving average of 27.11 and its 200-period average of 28.07, after CEO Albert Bourla’s $1 million share purchase, a second-quarter revenue beat, and a bullish BMO Capital note on Pfizer’s valuation.

Reading the Pfizer stock chart today

On the 15-minute chart, part of the technical analysis traders run on Pfizer, shares spent early August grinding higher between roughly $25.30 and $27.00, into the 4 August earnings release. A sharper move followed around 19 August, when price ran from near $27.40 to above $28.60 in a handful of sessions, tracking the earnings follow-through and the BMO Capital note below. ^[8]

Since then, price has pulled back in a stair-step pattern. As of the 08:58 UTC cut-off, Pfizer sits at $27.82, roughly $0.78 below the recent high near $28.60. The 50-period average, explained in Vantage’s moving average guide, sits at 27.11 and has climbed steadily since early August. The 200-period average, at 28.07, sits just above current price, leaving Pfizer shares trading squarely between the two.

Note: RSI and volume data did not render on the chart snapshot used here, so neither is referenced in this piece.

Pfizer’s two key reference levels compared:

Reference	Value	Position vs Price	As Of
50-period MA	27.11	Below current price	21 Aug 2026, 08:58 UTC
200-period MA	28.07	Above current price	21 Aug 2026, 08:58 UTC
Last price	27.82	Between the two averages	21 Aug 2026, 08:58 UTC

Table 1: Key moving-average reference levels as of 21 August 2026, 08:58 (UTC). Source: TradingView setup used for this analysis. Indicative only.

What’s moving the Pfizer stock price this week

Earnings and guidance

Pfizer’s second-quarter 2026 earnings report, released 4 August, beat consensus and coincided with the company raising the midpoint of full-year revenue guidance by $500 million while reaffirming adjusted EPS guidance. ^[1] CEO Albert Bourla called it another strong quarter. Vantage’s earnings report and earnings season guide cover how these releases tend to move share prices.

Analyst notes: two firms, same conclusion

BMO Capital’s Evan Seigerman has kept a constructive stance through August, maintaining an Outperform rating near $30 and pointing to Pfizer’s valuation discount against its US biopharma peers. ^[3][4] Guggenheim’s Vamil Divan has likewise held a constructive stance, with a reference level near $35, one of the more bullish figures on the Street. ^[3] Wall Street’s broader consensus is more cautious, a Hold near $28.28, putting BMO and Guggenheim toward the bullish end of that range. ^[5]

Insider activity and pipeline

Bourla’s roughly $1 million open-market purchase on 12 August, disclosed in a Form 4 filing, lifted his direct holdings to 429,173 shares. ^[6] Pfizer’s obesity-treatment programme, which management described as advancing with meaningful momentum on the Q2 call, remains part of the broader narrative among analysts.

What to watch

The following calendar items and levels sit alongside the wider stock market news traders are tracking for Pfizer and its peers:

• Q3 2026 Earnings, Early November: Pfizer’s next quarterly report will show whether the guidance raise holds and the pipeline updates keep progressing.
• Analyst Coverage: Any shift from BMO Capital, Guggenheim, or other covering firms away from their constructive stance is one signal some traders may watch for.
• 200-Period Moving Average, 28.07: Current price sits just under this level on the TradingView setup used for this analysis. A move through it, or a pullback toward 27.11, are both levels traders are monitoring.
• Dividend Schedule: Pfizer’s capital allocation framework, including its dividend, remains a focus for income-oriented holders following the Q2 update. ^[1]

Pfizer shares have moved through more than a $3 range in under three weeks, so intraday volatility has picked up. A Stop Loss does not prevent a loss outright, but it can limit losses to a planned size, worth revisiting given the recent swings. Traders holding Pfizer CFDs alongside other US equity exposure should also review their combined risk.

Leverage applies to Pfizer CFD positions in both directions, amplifying gains and losses alike, and works as a double-edged tool rather than a one-sided feature. Position sizing proportional to account equity is worth revisiting given the recent volatility. Traders exploring the wider opportunity set can browse Vantage’s US share CFDs.

RISK WARNING: CFDs are complex financial instruments and carry a high risk of losing money rapidly due to leverage. You should ensure you fully understand the risks involved and carefully consider whether you can afford to take the high risk of losing your money before trading.

Disclaimer: The information is provided for educational purposes only and doesn’t take into account your personal objectives, financial circumstances, or needs. It does not constitute investment advice. We encourage you to seek independent advice if necessary. The information has not been prepared in accordance with legal requirements designed to promote the independence of investment research. No representation or warranty is given as to the accuracy or completeness of any information contained within. This material may contain historical or past performance figures and should not be relied on. Furthermore estimates, forward-looking statements, and forecasts cannot be guaranteed. The information on this site and the products and services offered are not intended for distribution to any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

References

[1] “Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance – Business Wire” https://www.businesswire.com/news/home/20260804345420/en/Pfizer-Reports-Second-Quarter-Results-And-Raises-Midpoint-of-2026-Revenue-Guidance Accessed on 21 August 2026.

[2] “Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance – Pfizer.com Press Release” https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-results-and-raises-midpoint Accessed on 21 August 2026.

[3] “PFE builds bull case at $26 after earnings beat and insider buys – Investing.com” https://www.investing.com/news/stock-market-news/pfe-builds-bull-case-at-26-after-earnings-beat-and-insider-buys-93CH-4846732 Accessed on 21 August 2026.

[4] “Pfizer’s Strategic Acquisitions and Undervalued Position Drive Buy Rating – TipRanks” https://www.tipranks.com/news/ratings/pfizers-strategic-acquisitions-and-undervalued-position-drive-buy-rating-ratings Accessed on 21 August 2026.

[5] “Pfizer stock holds steady as investors weigh Q2 earnings beat and pipeline updates – AD HOC NEWS” https://www.ad-hoc-news.de/boerse/news/corporate-news/pfizer-stock-holds-steady-as-investors-weigh-q2-earnings-beat-and-pipeline/69969321 Accessed on 21 August 2026.

[6] “Pfizer CEO Albert Bourla Acquires 38,000 Shares in August 2026 Open-Market Purchase – Kalkine Media” https://kalkinemedia.com/us/news/announcements/pfizer-ceo-albert-bourla-acquires-38000-shares-in-august-2026-open-market-purchase Accessed on 21 August 2026.

[7] “Pfizer stock steadies after Q2 2026 beat and modest guidance lift – AD HOC NEWS” https://www.ad-hoc-news.de/boerse/news/corporate-news/pfizer-stock-steadies-after-q2-2026-beat-and-modest-guidance-lift/69946227 Accessed on 21 August 2026.

[8] “Pfizer stock hits a fresh 52-week high as Q2 2026 earnings beat and guidance lift support the rally – AD HOC NEWS” https://www.ad-hoc-news.de/boerse/news/corporate-news/pfizer-stock-hits-a-fresh-52-week-high-as-q2-2026-earnings-beat-and/69975181 Accessed on 21 August 2026.